Bristol-Myers Squibb/$BMY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Bristol-Myers Squibb
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Ticker
$BMY
Sector
Primary listing
NYSE
Employees
34,100
Headquarters
Website
BMY Metrics
BasicAdvanced
$94B
18.64
$2.49
0.37
$2.46
5.35%
Price and volume
Market cap
$94B
Beta
0.37
52-week high
$63.33
52-week low
$42.96
Average daily volume
9.9M
Dividend rate
$2.46
Financial strength
Current ratio
1.207
Quick ratio
1.043
Long term debt to equity
263.48
Total debt to equity
291.549
Dividend payout ratio (TTM)
98.12%
Interest coverage (TTM)
6.37%
Profitability
EBITDA (TTM)
19,114
Gross margin (TTM)
73.92%
Net profit margin (TTM)
10.58%
Operating margin (TTM)
26.49%
Effective tax rate (TTM)
23.18%
Revenue per employee (TTM)
$1,400,000
Management effectiveness
Return on assets (TTM)
8.34%
Return on equity (TTM)
29.32%
Valuation
Price to earnings (TTM)
18.641
Price to revenue (TTM)
1.973
Price to book
5.41
Price to tangible book (TTM)
-3.67
Price to free cash flow (TTM)
6.456
Free cash flow yield (TTM)
15.49%
Free cash flow per share (TTM)
7.178
Dividend yield (TTM)
5.31%
Forward dividend yield
5.35%
Growth
Revenue change (TTM)
2.57%
Earnings per share change (TTM)
-177.23%
3-year revenue growth (CAGR)
0.39%
10-year revenue growth (CAGR)
11.28%
3-year earnings per share growth (CAGR)
-6.29%
10-year earnings per share growth (CAGR)
8.79%
3-year dividend per share growth (CAGR)
5.25%
10-year dividend per share growth (CAGR)
5.28%
What the Analysts think about BMY
Analyst ratings (Buy, Hold, Sell) for Bristol-Myers Squibb stock.
Bulls say / Bears say
Bristol-Myers posted a 1% revenue increase to $12.3 billion in Q2 2025, beating consensus on robust 8% Eliquis and 7% Opdivo growth, and raised its full-year revenue and EPS guidance. (Reuters)
The March 2025 acquisition of 2seventy bio for $286 million gives Bristol-Myers full ownership of the CAR-T therapy Abecma, eliminating profit-sharing costs and bolstering its cell therapy pipeline. (Reuters)
In May 2025, Bristol-Myers and Sanofi settled Hawaii’s Plavix litigation for $700 million, resolving a decade-long dispute and removing a material overhang on U.S. operations. (Reuters)
BMY’s Cobenfy schizophrenia drug failed to meet its primary endpoint in a key late-stage trial announced in April 2025, disappointing investors and casting doubt on its growth prospects in psychiatry. (Reuters)
Cigna filed an antitrust suit in June 2025 alleging that Bristol-Myers engaged in anti-competitive tactics to maintain a Pomalyst monopoly, potentially risking billions in damages if unsuccessful. (Reuters)
Revenue from Revlimid declined 38% year-over-year in Q2 2025 due to generic competition, underscoring the challenge of offsetting losses from aging franchises. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2025.
BMY Financial Performance
Revenues and expenses
BMY Earnings Performance
Company profitability
BMY News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bristol-Myers Squibb stock?
Bristol-Myers Squibb (BMY) has a market cap of $94B as of September 17, 2025.
What is the P/E ratio for Bristol-Myers Squibb stock?
The price to earnings (P/E) ratio for Bristol-Myers Squibb (BMY) stock is 18.64 as of September 17, 2025.
Does Bristol-Myers Squibb stock pay dividends?
Yes, the Bristol-Myers Squibb (BMY) stock pays dividends to shareholders. As of September 17, 2025, the dividend rate is $2.46 and the yield is 5.35%. Bristol-Myers Squibb has a payout ratio of 98.12% on a trailing twelve-month basis.
When is the next Bristol-Myers Squibb dividend payment date?
The next Bristol-Myers Squibb (BMY) dividend payment date is unconfirmed.
What is the beta indicator for Bristol-Myers Squibb?
Bristol-Myers Squibb (BMY) has a beta rating of 0.37. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.